2-(3-(cyclobutylmethyl)-4-oxo-3,4-dihydrophthalazin-1-yl)-N-(pyridin-2-ylmethyl)acetamide

ID: ALA5180932

PubChem CID: 168275606

Max Phase: Preclinical

Molecular Formula: C21H22N4O2

Molecular Weight: 362.43

Names and Identifiers

Canonical SMILES:  O=C(Cc1nn(CC2CCC2)c(=O)c2ccccc12)NCc1ccccn1

Standard InChI:  InChI=1S/C21H22N4O2/c26-20(23-13-16-8-3-4-11-22-16)12-19-17-9-1-2-10-18(17)21(27)25(24-19)14-15-6-5-7-15/h1-4,8-11,15H,5-7,12-14H2,(H,23,26)

Standard InChI Key:  PEGAZEBDOLGIFH-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   -3.2147    1.0311    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5001    1.4434    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7882    1.0315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7882    0.2063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4983   -0.2054    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2147    0.2026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0735    1.4441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3588    1.0315    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3588    0.2062    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0735   -0.2063    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0735    2.2693    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3557    1.4441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0704    1.0315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8811    1.2487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.0947    0.4514    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2841    0.2342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0735   -1.0315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3588   -1.4441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3588   -2.2693    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3557   -1.0315    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.0704   -1.4441    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7851   -1.0315    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7853   -0.2062    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4983    0.2044    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2131   -0.2082    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.2147   -1.0294    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5028   -1.4459    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  1  6  1  0
  6  5  2  0
  3  7  1  0
  8  7  1  0
  9  8  1  0
 10  9  2  0
  4 10  1  0
  7 11  2  0
  8 12  1  0
 12 13  1  0
 14 13  1  0
 15 14  1  0
 15 16  1  0
 16 13  1  0
 10 17  1  0
 17 18  1  0
 18 19  2  0
 18 20  1  0
 20 21  1  0
 21 22  1  0
 23 22  2  0
 24 23  1  0
 25 24  2  0
 26 25  1  0
 27 26  2  0
 22 27  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5180932

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 362.43

Molecular Weight (Monoisotopic): 362.1743

AlogP: 2.45

#Rotatable Bonds: 6

Polar Surface Area: 76.88

Molecular Species: NEUTRAL

HBA: 5

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.27

CX Basic pKa: 4.14

CX LogP: 2.18

CX LogD: 2.18

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.73

Np Likeness Score: -1.77

References

1. Burley R, Hewer RC, Teall M, Dickson L, Ossola B, Russell S, Bender C, Cheung T, Powell JAC, Xu X, Brice NL, Otter L, Arimont M, Kidd SL, Vidal D, Dale JW, Mervin L, Sore HF, Mateu N, Lakshminarayana N, Dawson LA, Carlton M, Bürli RW..  (2022)  Synthesis and SAR of novel GPR39 agonists and positive allosteric modulators.,  61  [PMID:35123006] [10.1016/j.bmcl.2022.128607]

Source

Source(1):

• Scientific Literature